Drugs · acquisition-cost intelligence
Letairis
ambrisentan· ingredient ambrisentanAntihypertensives for pulmonary arterial hypertension· AMBRISENTAN 10 mg/1; AMBRISENTAN 5 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$8.52
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Medicare Part D coverage · CY2026
On 281 plan formularies · typical tier 5
Prior auth 99% · Step therapy 0% · Quantity limit 91% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.